Healthcare PharmaceuticalsPneumovax 23
Owned by Merck & Co.
Merck's 23-valent pneumococcal polysaccharide vaccine (PPSV23), FDA approved in 1983 as an expansion of Merck's 14-valent formulation licensed in 1977, providing T-cell independent immune protection against 23 pneumococcal serotypes in adults aged 50 and older and high-risk individuals, now used alongside conjugate vaccines per updated CDC recommendations.
vaccinepneumococcalppsv23